Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. In this work, we explored the antitumoral activity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Noblejas-López, María del Mar, Nieto-Jimenez, Cristina, Burgos, Miguel, Gómez-Juárez, Mónica, Montero, Juan Carlos, Esparís-Ogando, Azucena, Pandiella, Atanasio, Galán-Moya, Eva M., Ocaña, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717344/
https://www.ncbi.nlm.nih.gov/pubmed/31470872
http://dx.doi.org/10.1186/s13046-019-1387-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717344/
https://www.ncbi.nlm.nih.gov/pubmed/31470872
http://dx.doi.org/10.1186/s13046-019-1387-5

Ejemplares similares